Answers are grounded in this paper and cite their sources.
EDITOR—Three studies published in 1995-6 reported odds ratios for venous thromboembolic disease among women using third generation oral contraceptives compared with women using second generation products that were in the range 1.5 to 1.8.1-3 The design limitations and interpretation of the results of these studies have been widely questioned. A further study, based on computer records from 147 general practitioners in Britain, failed to show any significant difference in the risk of venous thromboembolic disease between generations of oral contraceptive.4
No takes yet. Share an insight, caveat, or question.
Farmer et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: